140 related articles for article (PubMed ID: 37634128)
21. Clinical and genetic analyses of patients with lateralized overgrowth.
Kim YM; Lee Y; Choi Y; Choi IH; Heo SH; Choi JM; Do HS; Jang JH; Yum MS; Yoo HW; Lee BH
BMC Med Genomics; 2022 Sep; 15(1):206. PubMed ID: 36175890
[TBL] [Abstract][Full Text] [Related]
22. BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer.
Bogani G; Chiappa V; Bini M; Ronzulli D; Indini A; Conca E; Raspagliesi F
Tumori; 2023 Apr; 109(2):244-248. PubMed ID: 35311394
[TBL] [Abstract][Full Text] [Related]
23. Patient-Reported Outcomes in Patients With
Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F
J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274
[TBL] [Abstract][Full Text] [Related]
24. A systematic review of the safety and efficacy of currently used treatment modalities in the treatment of patients with PIK3CA-related overgrowth spectrum.
Bernhard SM; Adam L; Atef H; Häberli D; Bramer WM; Minder B; Döring Y; Laine JE; Muka T; Rössler J; Baumgartner I
J Vasc Surg Venous Lymphat Disord; 2022 Mar; 10(2):527-538.e2. PubMed ID: 34358672
[TBL] [Abstract][Full Text] [Related]
25. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.
Parker VER; Keppler-Noreuil KM; Faivre L; Luu M; Oden NL; De Silva L; Sapp JC; Andrews K; Bardou M; Chen KY; Darling TN; Gautier E; Goldspiel BR; Hadj-Rabia S; Harris J; Kounidas G; Kumar P; Lindhurst MJ; Loffroy R; Martin L; Phan A; Rother KI; Widemann BC; Wolters PL; Coubes C; Pinson L; Willems M; Vincent-Delorme C; ; Vabres P; Semple RK; Biesecker LG
Genet Med; 2019 May; 21(5):1189-1198. PubMed ID: 30270358
[TBL] [Abstract][Full Text] [Related]
27. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG; Barrios DM; Blinder VS; Bromberg JF; Drullinsky PR; Funt SA; Jhaveri KL; Lake DE; Lyons T; Modi S; Razavi P; Sidel M; Traina TA; Vahdat LT; Lacouture ME
Breast Cancer Res Treat; 2020 Aug; 183(1):227-237. PubMed ID: 32613539
[TBL] [Abstract][Full Text] [Related]
28. A multidisciplinary approach to optimizing care of patients treated with alpelisib.
Rugo HS; Lacouture ME; Goncalves MD; Masharani U; Aapro MS; O'Shaughnessy JA
Breast; 2022 Feb; 61():156-167. PubMed ID: 35016012
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Sharma P; Abramson VG; O'Dea A; Nye L; Mayer I; Pathak HB; Hoffmann M; Stecklein SR; Elia M; Lewis S; Scott J; De Jong JA; Wang YY; Yoder R; Schwensen K; Finke K; Heldstab J; LaFaver S; Williamson SK; Phadnis MA; Reed GA; Kimler BF; Khan QJ; Godwin AK
Clin Cancer Res; 2021 Jul; 27(14):3896-3904. PubMed ID: 33602685
[TBL] [Abstract][Full Text] [Related]
30. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Mayer IA; Prat A; Egle D; Blau S; Fidalgo JAP; Gnant M; Fasching PA; Colleoni M; Wolff AC; Winer EP; Singer CF; Hurvitz S; Estévez LG; van Dam PA; Kümmel S; Mundhenke C; Holmes F; Babbar N; Charbonnier L; Diaz-Padilla I; Vogl FD; Sellami D; Arteaga CL
Clin Cancer Res; 2019 May; 25(10):2975-2987. PubMed ID: 30723140
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
32. Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome.
López Gutiérrez JC; Lizarraga R; Delgado C; Martínez Urrutia MJ; Díaz M; Miguel M; Triana P
J Pediatr Adolesc Gynecol; 2019 Dec; 32(6):648-650. PubMed ID: 31330249
[TBL] [Abstract][Full Text] [Related]
33. Clinical Response to PI3K-α Inhibition in a Cohort of Children and Adults With
Raghavendran P; Albers SE; Phillips JD; Zarnegar-Lumley S; Borst AJ
J Vasc Anom (Phila); 2022 Mar; 3(1):. PubMed ID: 36284525
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA vascular overgrowth syndromes: an update.
Hughes M; Hao M; Luu M
Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
[TBL] [Abstract][Full Text] [Related]
35. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
[TBL] [Abstract][Full Text] [Related]
36. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
[TBL] [Abstract][Full Text] [Related]
37. Low risk of embryonic and other cancers in PIK3CA-related overgrowth spectrum: Impact on screening recommendations.
Faivre L; Crépin JC; Réda M; Nambot S; Carmignac V; Abadie C; Mirault T; Faure-Conter C; Mazereeuw-Hautier J; Maza A; Puzenat E; Collonge-Rame MA; Bursztejn AC; Philippe C; Thauvin-Robinet C; Chevarin M; Abasq-Thomas C; Amiel J; Arpin S; Barbarot S; Baujat G; Bessis D; Bourrat E; Boute O; Chassaing N; Coubes C; Demeer B; Edery P; El Chehadeh S; Goldenberg A; Hadj-Rabia S; Haye D; Isidor B; Jacquemont ML; Van Kien PK; Lacombe D; Lehalle D; Lambert L; Martin L; Maruani A; Morice-Picard F; Petit F; Phan A; Pinson L; Rossi M; Touraine R; Vanlerberghe C; Vincent M; Vincent-Delorme C; Whalen S; Willems M; Marle N; Verkarre V; Devalland C; Devouassoux-Shisheboran M; Abad M; Rioux-Leclercq N; Bonniaud B; Duffourd Y; Martel J; Binquet C; Kuentz P; Vabres P
Clin Genet; 2023 Nov; 104(5):554-563. PubMed ID: 37580112
[TBL] [Abstract][Full Text] [Related]
38. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
[TBL] [Abstract][Full Text] [Related]
39. Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants.
Mussa A; Leoni C; Iacoviello M; Carli D; Ranieri C; Pantaleo A; Buonuomo PS; Bagnulo R; Ferrero GB; Bartuli A; Melis D; Maitz S; Loconte DC; Turchiano A; Piglionica M; De Luisi A; Susca FC; Bukvic N; Forleo C; Selicorni A; Zampino G; Onesimo R; Cappuccio G; Garavelli L; Novelli C; Memo L; Morando C; Della Monica M; Accadia M; Capurso M; Piscopo C; Cereda A; Di Giacomo MC; Saletti V; Spinelli AM; Lastella P; Tenconi R; Dvorakova V; Irvine AD; Resta N
J Med Genet; 2023 Feb; 60(2):163-173. PubMed ID: 35256403
[TBL] [Abstract][Full Text] [Related]
40. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
